Skip to main content
evidena care

Interactions

Cannabis and ADHD medication: interactions with Ritalin and others

What is known about cannabis combined with methylphenidate, lisdexamfetamine or atomoxetine: heart and circulation, liver enzymes and where data are missing.

Key points

  • There are only a few human studies on combining cannabis with ADHD medication. Much of the evidence comes from laboratory experiments.
  • In a small study, THC and methylphenidate together raised the heart rate more than either substance alone.
  • Atomoxetine is broken down mainly by the liver enzyme CYP2D6. CBD inhibited this enzyme in the laboratory, but a clinical interaction has not been studied.
  • Lisdexamfetamine is converted to dexamfetamine in the blood. Specific data on the combination with cannabis are lacking.
  • Never stop or change ADHD medication on your own. Make any change only in consultation with your doctor.

There are surprisingly few studies on cannabis and ADHD medication. The best documented effect is on the circulation: in a small controlled study, THC and methylphenidate, the active substance in Ritalin, Concerta and Medikinet, together raised the heart rate more than either substance alone. There are no data on clinically relevant changes in blood levels for any of the common ADHD medicines.1,2

For atomoxetine and methylphenidate, there are theoretical indications that CBD could affect their breakdown, because it inhibited the enzymes involved in the laboratory. For lisdexamfetamine (Elvanse), specific data are lacking. Whether a combination can be considered for you is assessed by your doctor. Never change your ADHD medication on your own.4,7

How cannabis and ADHD medication can affect each other

As with other medicines, there are two routes. Pharmacokinetically, one substance can change the breakdown of another, usually via liver enzymes. Pharmacodynamically, effects can add up directly, for example on heart rate, blood pressure, sleep or mood.2

A systematic review of interactions of THC, CBD and cannabis notes that clinical human data are lacking for most combinations. Many warnings are based on laboratory experiments. A shared breakdown pathway is a reason to look more closely, but not proof of a relevant interaction.2

Cannabis and methylphenidate (Ritalin, Concerta, Medikinet)

In a double-blind study, 16 healthy adults without ADHD who occasionally used cannabis received, over six sessions, all combinations of placebo or 10 mg THC and 0, 10 or 40 mg methylphenidate. THC and methylphenidate had additive effects on heart rate and cardiac workload. The peak heart rate averaged 89 with THC alone, 96 with THC and 10 mg methylphenidate, and 102 beats per minute with THC and 40 mg.1

102/min

mean peak heart rate with THC and 40 mg methylphenidate in a study of 16 peopleSource: Kollins et al. 2015

The combination also changed the subjective experience: participants rated certain effects of the combination differently from the individual substances. THC increased the number of errors in an attention test, while methylphenidate made reaction times more consistent. For working memory, THC weakened the accelerating effect of methylphenidate. The study was small and examined single doses, not long-term treatment for ADHD.1

Methylphenidate is broken down mainly by the enzyme carboxylesterase 1 (CES1), not primarily via CYP enzymes. Alcohol shows how sensitive this pathway is: in a study of 24 healthy people, levels of the active component of methylphenidate rose markedly with alcohol during the absorption phase.3 According to laboratory findings, CBD also inhibits CES1, among other enzymes. Whether this changes levels in people taking methylphenidate has not been studied.4

Cannabis and lisdexamfetamine (Elvanse)

Lisdexamfetamine is a prodrug: it is converted in the blood to dexamfetamine, which produces the actual effect. As a result, the active substance takes effect more slowly and lasts up to about 14 hours in adults.5

There are no specific studies on combining lisdexamfetamine with cannabis. The systematic review of cannabis interactions cites no clinical data for this combination. Because amfetamines, like methylphenidate, raise heart rate and blood pressure, it is reasonable to expect additive effects on the circulation here too. This is an inference, not a measured interaction.1,2

Cannabis and atomoxetine: CYP2D6 as a possible sticking point

Atomoxetine is not a stimulant. It is broken down mainly by the liver enzyme CYP2D6. How active this enzyme is varies genetically from person to person. In people with slow CYP2D6 metabolism, atomoxetine levels are considerably higher.6

In the laboratory, CBD inhibited the enzyme CYP2D6 more strongly than THC or cannabinol.7 In theory, CBD could therefore raise atomoxetine levels and intensify side effects such as palpitations, nausea or sleep disorders. There are no human studies on this combination. Whether the concentrations effective in the laboratory are reached in the body depends, among other things, on the amount of CBD.2,4

What is known about cannabis for ADHD itself

Some adults with ADHD report using cannabis for self-treatment. In a small randomised pilot study of 30 adults with ADHD, the cannabis spray Sativex was compared with placebo. For the primary outcome, attention and activity in testing, there was no significant difference. For individual secondary outcomes there were indications that did not remain significant after correction for multiple testing.8

There is therefore no established evidence that cannabis relieves ADHD symptoms. Cannabis is not a substitute for guideline-based ADHD therapy. In addition, daily use of high-THC cannabis was associated with a considerably increased risk of psychosis in a European study.8,9

What you should discuss with your doctor

  • which ADHD medicine you take, in which form and since when
  • whether you use CBD products or non-prescribed cannabis
  • heart disease, high blood pressure or heart rhythm disorders, including in your family
  • previous psychoses, mania or addiction
  • other medicines, such as antidepressants, that are also broken down via CYP2D6

After starting cannabis therapy, new palpitations, sleep disorders, inner restlessness or changes in mood are important feedback. With stimulants, monitoring heart rate and blood pressure may be useful. The study authors point out that cardiovascular effects of the combination deserve particular attention.1 Other combinations are explained in the articles Cannabis and medicines: which interactions matter?, Cannabis and antidepressants and Cannabis and blood pressure medication.

How it works at evidena

At evidena, a doctor reviews your entire medication in the consultation, including ADHD medicines, as well as your cardiovascular and mental health history. Whether cannabis therapy can be considered is decided individually by the doctor. A prescription is valid for a treatment period of 3 months and must be filled at a pharmacy within 1 month. You can book appointments at portal.evidena.care. We answer questions via WhatsApp or at info@evidena.care.

Conclusion

Little is known about cannabis and ADHD medication. A small study showed that THC and methylphenidate together raise the heart rate more. For atomoxetine and methylphenidate there are laboratory indications that CBD affects their breakdown; for lisdexamfetamine, data are lacking. Never change your ADHD medication on your own, only in consultation with your doctor.

This article is for general information and does not replace individual medical advice.

Frequently asked questions

May I take cannabis if I take Ritalin?

The combination is not ruled out in principle, but it has hardly been studied. Because effects on heart rate and blood pressure can add up, it is assessed by a doctor, especially if you have cardiovascular disease.

Does CBD strengthen the effect of atomoxetine?

That has not been shown. In the laboratory, CBD inhibited the enzyme CYP2D6, which breaks down atomoxetine. Whether this leads to higher levels in the body has not been studied.

Are there interactions between cannabis and Elvanse?

Specific studies are lacking. As with other stimulants, it is conceivable that effects on the circulation add up. This belongs in the medical assessment.

Can cannabis replace Ritalin?

No. There is no established evidence from large studies for cannabis in ADHD. Never change or stop your ADHD medication on your own, only in consultation with your doctor.

Which warning signs should I take seriously?

Racing heart, chest pain, severe restlessness, sleeplessness, mistrust or perceptual disturbances. For chest pain or fainting, call 144.

Your situation is individual

Discuss your questions with a doctor.

Book a consultation

Sources

  1. Kollins SH et al. An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. J Subst Abuse Treat. 2015;48(1):96–103. doi:10.1016/j.jsat.2014.07.014
  2. Nachnani R et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. doi:10.3389/fphar.2024.1282831
  3. Patrick KS et al. Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. Drug Metab Dispos. 2013;41(1):197–205. doi:10.1124/dmd.112.048595
  4. Stöllberger C et al. Cannabidiol's impact on drug-metabolization. Eur J Intern Med. 2023;118:6–13. doi:10.1016/j.ejim.2023.07.029
  5. Ermer JC et al. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. Clin Drug Investig. 2016;36(5):341–356. doi:10.1007/s40261-015-0354-y
  6. Sauer JM et al. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–590. doi:10.2165/00003088-200544060-00002
  7. Yamaori S et al. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011;39(11):2049–2056. doi:10.1124/dmd.111.041384
  8. Cooper RE et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795–808. doi:10.1016/j.euroneuro.2017.05.005
  9. Di Forti M et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–436. doi:10.1016/S2215-0366(19)30048-3

Written by evidena.care editorial team · Published 13 November 2026 · Reviewed 13 November 2026

This article is general information and does not replace medical advice. Whether cannabis therapy is an option for you is decided by a doctor in a personal consultation.